Amarin logo

AmarinNASDAQ: AMRN

Profile

Sector:

Healthcare

Country:

Ireland

IPO:

01 April 1993

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$205.67 M
-86%vs. 3y high
54%vs. sector
-vs. 3y high
-vs. sector
-83%vs. 3y high
23%vs. sector
-68%vs. 3y high
21%vs. sector

Price

after hours | Wed, 20 Nov 2024 00:39:23 GMT
$0.50$0.00(0.00%)

Dividend

No data over the past 3 years
$42.30 M$37.46 M
$42.30 M-$25.13 M

Analysts recommendations

Institutional Ownership

AMRN Latest News

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
globenewswire.com09 September 2024 Sentiment: POSITIVE

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of VASCEPA®/VAZKEPA (icosapent ethyl) in patients with diabetes and high cardiovascular risk and the anti-Lp(a) oxidation mechanistic effects of eicosapentaenoic acid (EPA) will be presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting September 9 – 13, 2024 in Madrid, Spain.

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
globenewswire.com22 August 2024 Sentiment: POSITIVE

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® cardiovascular outcomes trial with VASCEPA®/VAZKEPA® (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid (EPA) that will be presented at the European Society of Cardiology (ESC) Congress in London, United Kingdom, August 30 – September 2, 2024.

Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat
zacks.com01 August 2024 Sentiment: NEUTRAL

Amarin's (AMRN) second-quarter 2024 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
globenewswire.com31 July 2024 Sentiment: POSITIVE

-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation – -- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA Performance Globally -- -- Leadership Transition Completed with Appointment of Aaron Berg as President and CEO -- DUBLIN and BRIDGEWATER, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the second quarter ended June 30, 2024, and provided a business update.

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
globenewswire.com17 July 2024 Sentiment: POSITIVE

-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA® in Europe --

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
globenewswire.com17 July 2024 Sentiment: POSITIVE

DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET.

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
globenewswire.com08 July 2024 Sentiment: POSITIVE

-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- -- EddingPharm Now Working to Prepare for National Reimbursement and Drug Listing (NRDL) and Enhance the Commercial Launch of VASCEPA Across Mainland China --

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok
globenewswire.com07 June 2024 Sentiment: POSITIVE

LA BOUTIQUE, the leading Thai fashion designer brand celebrated for its neo-romantic and new vintage aesthetic, is thrilled to announce the grand opening of its latest flagship store at Gaysorn Amarin LA BOUTIQUE, the leading Thai fashion designer brand celebrated for its neo-romantic and new vintage aesthetic, is thrilled to announce the grand opening of its latest flagship store at Gaysorn Amarin

Amarin Board of Directors Announces CEO Transition
globenewswire.com04 June 2024 Sentiment: NEUTRAL

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities --

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research03 May 2024 Sentiment: POSITIVE

Here is a comparison of the performance of Amarin (AMRN) and ANI Pharmaceuticals (ANIP) within their sector for the year to date.

  • 1(current)
  • 2

What type of business is Amarin?

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

What sector is Amarin in?

Amarin is in the Healthcare sector

What industry is Amarin in?

Amarin is in the Drug Manufacturers - General industry

What country is Amarin from?

Amarin is headquartered in Ireland

When did Amarin go public?

Amarin initial public offering (IPO) was on 01 April 1993

What is Amarin website?

https://www.amarincorp.com

Is Amarin in the S&P 500?

No, Amarin is not included in the S&P 500 index

Is Amarin in the NASDAQ 100?

No, Amarin is not included in the NASDAQ 100 index

Is Amarin in the Dow Jones?

No, Amarin is not included in the Dow Jones index

When was Amarin the previous earnings report?

No data

When does Amarin earnings report?

The next expected earnings date for Amarin is 28 February 2025